NASDAQ:FRLN

Freeline Therapeutics Competitors

$12.42
+0.28 (+2.31 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.10
Now: $12.42
$12.71
50-Day Range
$12.05
MA: $13.71
$15.25
52-Week Range
$11.85
Now: $12.42
$21.69
Volume3,976 shs
Average Volume8,689 shs
Market Capitalization$445.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Freeline Therapeutics (NASDAQ:FRLN) Vs. KYMR, KRYS, SGMO, IMVT, RGNX, and ALVR

Should you be buying FRLN stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Freeline Therapeutics, including Kymera Therapeutics (KYMR), Krystal Biotech (KRYS), Sangamo Therapeutics (SGMO), Immunovant (IMVT), REGENXBIO (RGNX), and AlloVir (ALVR).

Kymera Therapeutics (NASDAQ:KYMR) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Kymera Therapeutics and Freeline Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02502.71
Freeline Therapeutics01602.86

Kymera Therapeutics presently has a consensus target price of $48.6667, suggesting a potential upside of 25.88%. Freeline Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 101.29%. Given Freeline Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Freeline Therapeutics is more favorable than Kymera Therapeutics.

Profitability

This table compares Kymera Therapeutics and Freeline Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Freeline TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Kymera Therapeutics and Freeline Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Freeline TherapeuticsN/AN/AN/AN/AN/A

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are owned by institutional investors. Comparatively, 38.5% of Freeline Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Freeline Therapeutics beats Kymera Therapeutics on 4 of the 4 factors compared between the two stocks.

Krystal Biotech (NASDAQ:KRYS) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Earnings & Valuation

This table compares Krystal Biotech and Freeline Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-64.44
Freeline TherapeuticsN/AN/AN/AN/AN/A

Institutional & Insider Ownership

73.1% of Krystal Biotech shares are owned by institutional investors. Comparatively, 38.5% of Freeline Therapeutics shares are owned by institutional investors. 27.4% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Krystal Biotech and Freeline Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Krystal Biotech00603.00
Freeline Therapeutics01602.86

Krystal Biotech currently has a consensus price target of $101.00, suggesting a potential upside of 30.61%. Freeline Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 101.29%. Given Freeline Therapeutics' higher probable upside, analysts plainly believe Freeline Therapeutics is more favorable than Krystal Biotech.

Profitability

This table compares Krystal Biotech and Freeline Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Krystal BiotechN/A-10.72%-10.40%
Freeline TherapeuticsN/AN/AN/A

Sangamo Therapeutics (NASDAQ:SGMO) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

57.7% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 38.5% of Freeline Therapeutics shares are held by institutional investors. 1.8% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Sangamo Therapeutics and Freeline Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sangamo Therapeutics02402.67
Freeline Therapeutics01602.86

Sangamo Therapeutics currently has a consensus price target of $20.20, suggesting a potential upside of 75.96%. Freeline Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 101.29%. Given Freeline Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Freeline Therapeutics is more favorable than Sangamo Therapeutics.

Earnings and Valuation

This table compares Sangamo Therapeutics and Freeline Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$102.43 million16.11$-95,190,000.00($0.85)-13.51
Freeline TherapeuticsN/AN/AN/AN/AN/A

Freeline Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics.

Profitability

This table compares Sangamo Therapeutics and Freeline Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sangamo Therapeutics-51.51%-16.32%-9.85%
Freeline TherapeuticsN/AN/AN/A

Summary

Freeline Therapeutics beats Sangamo Therapeutics on 6 of the 9 factors compared between the two stocks.

Freeline Therapeutics (NASDAQ:FRLN) and Immunovant (NASDAQ:IMVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Institutional & Insider Ownership

38.5% of Freeline Therapeutics shares are held by institutional investors. Comparatively, 40.2% of Immunovant shares are held by institutional investors. 0.2% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Freeline Therapeutics and Immunovant, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Freeline Therapeutics01602.86
Immunovant011402.93

Freeline Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 101.29%. Immunovant has a consensus target price of $45.60, suggesting a potential upside of 195.72%. Given Immunovant's stronger consensus rating and higher probable upside, analysts plainly believe Immunovant is more favorable than Freeline Therapeutics.

Earnings and Valuation

This table compares Freeline Therapeutics and Immunovant's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Freeline TherapeuticsN/AN/AN/AN/AN/A
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.01

Profitability

This table compares Freeline Therapeutics and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Freeline TherapeuticsN/AN/AN/A
ImmunovantN/A-34.80%-32.38%

Summary

Immunovant beats Freeline Therapeutics on 5 of the 7 factors compared between the two stocks.

Freeline Therapeutics (NASDAQ:FRLN) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Profitability

This table compares Freeline Therapeutics and REGENXBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Freeline TherapeuticsN/AN/AN/A
REGENXBIO-63.13%-21.73%-18.74%

Analyst Ratings

This is a summary of current ratings and price targets for Freeline Therapeutics and REGENXBIO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Freeline Therapeutics01602.86
REGENXBIO02512.88

Freeline Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 101.29%. REGENXBIO has a consensus target price of $62.50, suggesting a potential upside of 81.11%. Given Freeline Therapeutics' higher probable upside, research analysts plainly believe Freeline Therapeutics is more favorable than REGENXBIO.

Institutional & Insider Ownership

38.5% of Freeline Therapeutics shares are held by institutional investors. Comparatively, 75.2% of REGENXBIO shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Freeline Therapeutics and REGENXBIO's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Freeline TherapeuticsN/AN/AN/AN/AN/A
REGENXBIO$35.23 million41.64$-94,730,000.00($3.26)-10.59

Freeline Therapeutics has higher earnings, but lower revenue than REGENXBIO.

AlloVir (NASDAQ:ALVR) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Valuation and Earnings

This table compares AlloVir and Freeline Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/AN/AN/AN/A
Freeline TherapeuticsN/AN/AN/AN/AN/A

Institutional and Insider Ownership

32.1% of AlloVir shares are owned by institutional investors. Comparatively, 38.5% of Freeline Therapeutics shares are owned by institutional investors. 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares AlloVir and Freeline Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AlloVirN/AN/AN/A
Freeline TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for AlloVir and Freeline Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AlloVir00403.00
Freeline Therapeutics01602.86

AlloVir currently has a consensus target price of $48.75, suggesting a potential upside of 120.79%. Freeline Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 101.29%. Given AlloVir's stronger consensus rating and higher possible upside, equities analysts clearly believe AlloVir is more favorable than Freeline Therapeutics.

Summary

AlloVir beats Freeline Therapeutics on 3 of the 5 factors compared between the two stocks.


Freeline Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.66+0.3%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
News Coverage
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33+0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48+2.5%$1.65 billion$102.43 million-19.13Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$15.42+3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51+3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
AlloVir logo
ALVR
AlloVir
1.4$22.08+2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84+4.5%$1.42 billion$7.80 million-17.61Gap Down
Alector logo
ALEC
Alector
1.3$17.80+3.8%$1.42 billion$21.22 million-7.98Gap Down
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.55+1.1%$1.40 billionN/A0.00Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$29.96+3.8%$1.39 billionN/A-16.93Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.65+10.4%$1.21 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.94+0.7%$1.16 billion$32.16 million-10.16Analyst Upgrade
Decrease in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$38.70+0.1%$1.14 billionN/A-16.12Analyst Downgrade
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.28+5.0%$1.11 billionN/A-2.87News Coverage
Ocugen logo
OCGN
Ocugen
1.1$5.78+6.4%$1.09 billionN/A-3.91Increase in Short Interest
Gap Down
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77+0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39+1.0%$1.05 billion$356.07 million7.05
Curis logo
CRIS
Curis
1.3$11.49+6.3%$1.05 billion$10 million-14.01Increase in Short Interest
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22+7.0%$935.20 millionN/A0.00Increase in Short Interest
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86+2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Gap Up
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01+6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$23.75+0.2%$905.75 millionN/A-9.81Increase in Short Interest
Analyst Revision
News Coverage
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86+4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86+6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Down
Passage Bio logo
PASG
Passage Bio
1.8$15.88+8.3%$854.84 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.40+0.5%$829.93 million$22.99 million-10.32
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.61+3.2%$824.27 millionN/A0.00Lockup Expiration
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25+3.9%$809.32 million$69.89 million-4.12News Coverage
Gap Down
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93+2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
News Coverage
Gap Down
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02+5.3%$744.64 million$2.51 million-3.65
Inhibrx logo
INBX
Inhibrx
1.6$18.03+16.4%$680.60 millionN/A0.00Decrease in Short Interest
Gap Down
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.04+3.5%$663.63 million$14.75 million-2.59Increase in Short Interest
News Coverage
Gap Down
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00+1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
News Coverage
Vaxart logo
VXRT
Vaxart
1.3$5.35+1.5%$630.05 million$9.86 million-9.07News Coverage
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.08+1.6%$623.24 million$13.29 million-9.99Gap Down
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.59+0.8%$615.82 millionN/A0.00Analyst Downgrade
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.61+7.1%$586.59 millionN/A0.00Lockup Expiration
Compugen logo
CGEN
Compugen
1.4$8.57+3.9%$586.36 million$17.80 million-23.16Analyst Report
News Coverage
Gap Down
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.04+2.6%$538.67 millionN/A-2.45Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.62+1.5%$536.28 million$150.05 million-2.40News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.55+4.1%$531.02 millionN/A-1.25
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.45+4.4%$529.86 millionN/A-5.89Gap Down
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.77+1.9%$501.14 million$22.24 million-4.36Increase in Short Interest
Gap Down
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.12+7.0%$454.86 millionN/A-8.00Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$10.35+11.1%$430.79 millionN/A-3.14Analyst Upgrade
News Coverage
Gap Down
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.64+2.4%$422.95 million$4.36 million-3.02
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.09+6.8%$412.63 million$147.87 million-3.02Gap Down
Opthea logo
OPT
Opthea
1.5$9.10+0.4%$395.46 millionN/A0.00Lockup Expiration
Gap Down
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.70+0.1%$353.95 millionN/A0.00
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$8.44+3.2%$353.17 millionN/A0.00Analyst Report
Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.